长效干扰素治疗慢性乙型肝炎e抗原阴性患者疗效研究

The therapeutic effect of peginterferon capsule on patients infected with HBeAg-negative chronic hepatitis B

目的 观察长效干扰素对慢性乙型肝炎HBeAg阴性患者的临床疗效.方法 将46例HBeAg阴性慢性乙肝患者随机分为两组,其中长效干扰素组：派罗欣180μg,一周一次,皮下注射,疗程48周;普通干扰素组：赛诺金500MU,肌肉注射,隔日一次,疗程48周.治疗结束后随访24周.结果 长效干扰素组和普通干扰素组的ALT水平复常率在治疗结束和随访结束比较,差异有统计学意义（x2 =9.106,P＜0.05;x2=9.832,P＜0.05）.长效干扰素组和普通干扰素组的HBV-DNA阴转率在治疗结束和随访结束比较,差异有统计学意义（x2 =4.312,P＜0.05;x2=6.158,P＜0.05）.但两组在HBV-DNA下降程度上无明显差别（P＞0.05）.结论 长效干扰素治疗慢性乙型肝炎e抗原阴性患者可以明显提高疗效.

Objective To estimate the therapeutic effect of peginterferon and interferon capsule on patients with HBeAg-negative chronic hepatitis B. Methods 46 HBeAg-negative chronic hepatitis B pa- tients were randomly divided into two groups. The peginterferon group： peginterferon 180p,g, once a week, for 48 weeks. The interferon group ： interferon 500MU, three times a week, for 48 weeks. All patients were followed for 24 weeks after treatments. Results Up to the end of the study and the end of follow-up at the 24th weeks, between peginterferon group and interferon group, there were statistical significances in ALT nor- malization rates （x2 = 9. 106, P 〈 0. 05 ; X2 = 9. 832, P 〈 0.05 ） and HBV-DNA negativity rates （X2 = 4. 312, P 〈 0. 05; X2 = 6. 158, P 〈0. 05） , but there were no statistical significances in serum HBV-DNA reduction（P 〉 0. 05） Conclusions Peginterferon capsule has better therapeutic effect on HBeAg-negative chronic hepatitis B.